It's bad news for Purdue Pharma but good news for generics makers such as Teva Pharmaceutical Industries. A federal appeals court affirmed a lower court's decision to toss out some Purdue's patents for its top-selling pain drug OxyContin, further opening the door to cheap knockoff versions of the med.
Last week, Novartis' Sandoz unveiled weak numbers, blaming them on broader generics-industry trends. But at least one analyst isn't convinced that's the culprit.
It's a dark day at Novartis. Sun Pharma rolled out its copycat version of Novartis' blockbuster cancer drug Gleevec, setting the Swiss drugmaker up for a big hit to 2016 sales.
On Monday, Amgen said the FDA had accepted its application for its biosimilar of AbbVie's Humira, so-called ABP 501--but earlier this month, the U.S. Patent and Trademark Office shut down its challenge to Humira's patents.
Amgen and Pfizer's Enbrel officially has a biosimilar rival in Europe. And if the rollout goes anything like the recent EU launch of Remicade copy Remsima, the blockbuster brand will be in trouble.
Amgen has hit a potential snag in its quest to bring a biosimilar of AbbVie cash cow Humira to market. Thursday, the U.S. Patent and Trademark Office declined to review a pair of formulation patents on the arthritis drug, determining that "based on the petition and the accompanying evidence … Amgen has not shown a reasonable likelihood of prevailing on any of its challenges," Reuters reports.
SAN FRANCISCO-- After watching months of pharma's M&A wave from the sidelines, Teva finally made a splash this summer with an agreement to pick up Allergan's generics business. And it may not be finished in the dealmaking arena.
Roche is burying the hatchet with India's Glenmark in a patent war over its cancer drug Tarceva, settling outstanding litigation with the company even as it wages a battle with another Indian generics maker over a patent for the med.
Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) can add some ammo to their drug price-fighting arsenal, as a new report shows that Medicaid could have saved $1.4 billion over the last 10 years if companies were forced to offer discounts if prices for top-selling generic drugs surpassed the rate of inflation.
Apotex is working on a biosimilar of Amgen's Neulasta, but if and when it wins FDA approval, it'll have to wait awhile before launching, a court ruled on Wednesday.